The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways
Open accessAbstract
Although the nucleotide‐binding oligomerization domain‐ (NOD‐) like receptor pyrin domain containing 3 (NLRP3) inflammasome has been recently detected in the heart, its role in cardiac ischemia/reperfusion (IR) is still controversial. Here, we investigate whether a pharmacological modulation of NLRP3 inflammasome exerted protective effects in an ex vivo model of IR injury. Isolated hearts from male Wistar rats (5‐6 months old) underwent ischemia (30 min) followed by reperfusion (20 or 60 min) with and without pretreatment with the recently synthetized NLRP3 inflammasome inhibitor INF4E (50 μ M, 20 min before ischemia). INF4E exerted protection against myocardial IR, shown by a significant reduction in infarct size and lactate dehydrogenase release and improvement in postischemic left ventricular pressure. The formation of the NLRP3 inflammasome complex was induced by myocardial IR and attenuated by INF4E in a time‐dependent way. Interestingly, the hearts of the INF4E‐pretreated animals displayed a marked improvement of the protective RISK pathway and this effect was associated increase in expression of markers of mitochondrial oxidative phosphorylation. Our results demonstrate for the first time that INF4E protected against the IR‐induced myocardial injury and dysfunction, by a mechanism that involves inhibition of the NLRP3 inflammasome, resulting in the activation of the prosurvival RISK pathway and improvement in mitochondrial function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602 · cited 1×
“Pharmacological Inhibition of NLRP3 Inflammasome”
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e318282ab8f · Cited by 1,294
Kawaguchi, M., Takahashi, M., Hata, T., Kashima, Y., Usui, F., Morimoto, H., Izawa, A., Takahashi, Y., Masumoto, J., Koyama, J., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.982777 · Cited by 884
Kummer, J. A., Broekhuizen, R., Everett, H., Agostini, L., Kuijk, L., Martinon, F., Bruggen, R. V., & Tschopp, J. (2007) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.6a7101.2006 · Cited by 531
Mitochondria: diversity in the regulation of the NLRP3 inflammasome
Gurung, P., Lukens, J. R., & Kanneganti, T.-D. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.11.008 · Cited by 393
K+ regulates Ca2+ to drive inflammasome signaling: dynamic visualization of ion flux in live cells
Yaron, J. R., Gangaraju, S., Rao, M. Y., Kong, X., Zhang, L., Su, F., Tian, Y., Glenn, H. L., & Meldrum, D. R. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.277 · Cited by 212
Cited by
Pyroptosis in inflammatory diseases and cancer
Rao, Z., Zhu, Y., Yang, P., Chen, Z., Xia, Y., Qiao, C., Liu, W., Deng, H., Li, J., Ning, P., et al. (2022) · Theranostics · doi:10.7150/thno.71086 · Cited by 800
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
The NLRP3 inflammasome in acute myocardial infarction
Toldo, S., & Abbate, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.161 · Cited by 665
The role of mitochondria in NLRP3 inflammasome activation
Liu, Q., Zhang, D., Hu, D., Zhou, X., & Zhou, Y. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.09.010 · Cited by 475
NLRP3 inflammasome in neurological diseases, from functions to therapies
Song, L., Pei, L., Yao, S., Wu, Y., & Shang, Y. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00063 · Cited by 467
Diverse roles of mitochondria in ischemic stroke
Yang, J.-L., Mukda, S., & Chen, S.-D. (2018) · Redox Biology · doi:10.1016/j.redox.2018.03.002 · Cited by 449
Regulated cell death in myocardial ischemia–reperfusion injury
Xiang, Q., Yi, X., Zhu, X.-H., Wei, X., & Jiang, D.-S. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.10.010 · Cited by 448
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury
Toldo, S., Mauro, A. G., Cutter, Z., & Abbate, A. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00158.2018 · Cited by 369
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
The role of inflammasomes in kidney disease
Komada, T., & Muruve, D. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0158-z · Cited by 304
Colchicine in Cardiovascular Disease: In-Depth Review
Deftereos, S. G., Beerkens, F. J., Shah, B., Giannopoulos, G., Vrachatis, D. A., Giotaki, S. G., Siasos, G., Nicolas, J., Arnott, C., Patel, S., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056171 · Cited by 273
Inflammasomes in Tissue Damages and Immune Disorders After Trauma
Bortolotti, P., Faure, E., & Kipnis, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01900 · Cited by 257
NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy
Luo, B., Huang, F., Liu, Y., Liang, Y., Wei, Z., Ke, H., Zeng, Z., Huang, W., & He, Y. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00519 · Cited by 213
“…to development of autoimmune and even metabolic diseases, such as DCM. Identification of NLRP3 inflammasome platforms is the main breakthrough on DCM research, as it is in the area of HF (Butts et al., 2015) and other cardiometabolic diseases (Janket et al., 2015; Mastrocola et al., 2016a).”
BackgroundInfluentialMetaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome
Mastrocola, R., Aragno, M., Alloatti, G., Collino, M., Penna, C., & Pagliaro, P. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170407123522 · Cited by 76
“molecule as promising selective inhibition of NLRP3 [45].”
BackgroundSelf-citationMetaflammation in glucolipid metabolic disorders: Pathogenesis and treatment
Xiong, P., Zhang, F., Liu, F., Zhao, J., Huang, X., Luo, D., & Guo, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114545 · Cited by 59
Metadata
- Authors
- Mastrocola, R., Penna, C., Tullio, F., Femminò, S., Nigro, D., Chiazza, F., Serpe, L., Collotta, D., Alloatti, G., Cocco, M., Bertinaria, M., Pagliaro, P., Aragno, M., & Collino, M.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2016-01
- Volume
- 2016
- Issue
- 1
- Pages
- 5271251-5271251
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W2560280719
- Cited by
- 158
- References
- 8
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.